Cancer Medicine,

A U.S. population‐based study of insurance disparities in cancer survival among adolescents and young adults

We utilized the Surveillance, Epidemiologic, and End Results database to identify 66 556 adolescents and young adults patients between 2007 and 2014 with 10 International Classification of Childhood Cancer diagnoses and calculated the Cox proportional hazard ratios of death for those with public or no insurance status compared to private insurance. Insurance status was a statistically significant predictor of death for lymphoid leukemia (age 15‐19, 30‐34, and 35‐39), acute myeloid leukemia (age 15‐19...

Cancer Medicine

Wed Jun 26, 2019 11:24

Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma‐related epilepsy

This is the first clinical practice guideline for glioma‐related epilepsy (GRE).·It was completed under the cooperation of epileptologists and neurosurgeons.·It provides recommendations for diagnostic and therapeutic procedures of GRE. Abstract Background Glioma‐related epilepsy (GRE) is defined as symptomatic epileptic seizures secondary to gliomas, it brings both heavy financial and psychosocial burdens to patients with diffuse glioma and significantly decreases their quality of life. To date,...

Cancer Medicine

Wed Jun 26, 2019 11:18

Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene

The subset of patients with colorectal cancer harboring pathogenic exonuclease domain mutations in the POLE gene had an extremely high tumor mutation burden. These tumors had distinctive characteristics clinically and genetically. Abstract Here, we investigated the clinicopathological and mutation profiles of colorectal cancer (CRC) with POLE mutations. Whole‐exome sequencing was performed in 910 surgically resected primary CRCs. Tumors exceeding 500 counts of nonsynonymous single...

Cancer Medicine

Tue Jun 25, 2019 19:59

Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12

Chimeric antigen receptor T cells (CAR‐T cells) have been successfully used in treatments of hematological tumors, however, their anti‐tumor activity in solid tumor treatments was limited. These work used several types of solid tumors to confirm the significantly enhanced anti‐tumor activity of CEA‐CAR‐T cells by combination use of a cytokine such as rhIL‐12. Abstract Background aims Chimeric antigen receptor T cells (CAR‐T cells) have been successfully used in treatments of hematological tumors,...

Cancer Medicine

Tue Jun 25, 2019 11:40